CVS Stock Decline Summary CVS Health shares declined 13.24% following the Trump administration's proposal to keep Medicare Advantage payment rates nearly flat at 0.09% increase for 2027, significantly below Wall Street's anticipated 4-6% increase. Key facts: - The Trump administration proposed near-flat Medicare Advantage rates for 2027 - Wall Street analysts had expected a 5% payment boost - CVS shares gapped down approximately 11.5% after Bank of America lowered its price target from $100 to $95 while maintaining a "Buy" rating - The broader health insurance sector experienced significant losses, with the selloff erasing approximately $92 billion in market value across multiple insurers - CVS also faced scrutiny from a House Judiciary antitrust probe into the company's pharmacy practices - Analyst consensus remains "Moderate Buy" with an average price target of $94.86
Read full analysisCVS Stock Decline Summary CVS Health shares declined 13.24% following the Trump administration's proposal to keep Medicare Advantage payment rates nearly flat at 0.09% increase for 2027, significantly below Wall Street's anticipated 4-6% increase. Key facts: - The Trump administration proposed near-flat Medicare Advantage rates for 2027 - Wall Street analysts had expected a 5% payment boost - CVS shares gapped down approximately 11.5% after Bank of America lowered its price target from $100 to $95 while maintaining a "Buy" rating - The broader health insurance sector experienced significant losses, with the selloff erasing approximately $92 billion in market value across multiple insurers - CVS also faced scrutiny from a House Judiciary antitrust probe into the company's pharmacy practices - Analyst consensus remains "Moderate Buy" with an average price target of $94.86
CVS Health (CVS) is a publicly traded company in the Healthcare sector.